Characteristics and treatment results of patients with gastroenteropancreatic neuroendocrine tumors in a tertiary care centre

Table 3 Multivariate analysis for OS and PFS for patients with GEP-NET

	5-year OS^a HR^b (95% CI^c)	P-value^d	5-year PFS^e HR (95% CI)	P-value
WHO 2017 classification		< 0.001		< 0.001
Well-differentiated, G1^f	1		1
Well-differentiated, G2	0.91 (0.17–5.0)	0.9	2.0 (0.88–4.8)	0.09
Well-differentiated, G3	11.3 (2.5–51.3)	0.002	7.0 (2.4–20.3)	< 0.001
Neuroendocrine carcinoma	40.1 (7.8–206.3)	< 0.001	14.8 (4.1–54.2)	< 0.001

^a OS Overall survival, ^b HR Hazard ratio, ^c CI Confidence interval, ^d p-value by log-rank test, ^ePFS Progression-free survival, ^f G Grade

ISSN: 1472-6823